Apr 08, 2019
MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts
Mar 29, 2019
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Mar 29, 2019
FDA approves new oral treatment for multiple sclerosis
Mar 27, 2019
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
Feb 28, 2019
EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019
Feb 25, 2019
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
Dec 17, 2018
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Dec 17, 2018
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
Nov 14, 2018
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
Oct 12, 2018
Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS
Oct 10, 2018
MAVENCLAD (Cladribine Tablets) Safety Profile in Multiple Sclerosis (MS) Reaffirmed with up to 10-Years of Follow-up Data
Oct 09, 2018
Uptake of Biogen's Tecfidera and Increased Availability of Merck KGaA's Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva's Copaxone
Jun 26, 2018
A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech's Ocrevus Prescribing Patterns
Jun 15, 2018
Stem Cell Therapy for Multiple Sclerosis Pipeline Analysis Report 2018 Featuring American CryoStem, Athersys, Celgene Cellular Therapeutics & Cell Cure Neurosciences
Mar 13, 2018
Genentech's Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play
Feb 26, 2018
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
Dec 11, 2017
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone® 40 mg/mL
Dec 07, 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Dec 04, 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Nov 27, 2017
MS Patients Who Adhere to Treatment Have Higher Health Costs-And Better Outcomes